Digital Remote Monitoring Trial Opens for ATTR-CM: Evaluating Luscii Platform Acceptance Among Clinicians and Patients

References

1. 1.Bayer. (2024). An Observational Study to Learn More About How Acceptable and Practical a Digital Remote Monitoring Tool (Luscii) is in People With Transthyretin Amyloid Cardiomyopathy (ATTR-CM). ClinicalTrials.gov. NCT07557147. https://clinicaltrials.gov/study/NCT07557147
2. 2.Gonzalez-Lopez, E., Gallego-Delgado, M., Guzzo-Merello, G., de Haro-Del Moral, F. J., Cobo-Marcos, M., Robles, C., Bornstein, B., Salas, C., Lara-Pezzi, E., Alonso-Pulpon, L., & Garcia-Pavia, P. (2015). Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal, 36(38), 2585-2594. https://doi.org/10.1093/eurheartj/ehv338
3. 3.Grogan, M., Scott, C. G., Kyle, R. A., Zeldenrust, S. R., Gertz, M. A., Lin, G., Klarich, K. W., Miller, W. L., Maleszewski, J. J., & Dispenzieri, A. (2016). Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. Journal of the American College of Cardiology, 68(10), 1014-1020. https://doi.org/10.1016/j.jacc.2016.06.033
4. 4.Koehler, F., Winkler, S., Schieber, M., Sechtem, U., Stangl, K., Böhm, M., Boll, H., Baumann, G., Honold, M., Koehler, K., Gelbrich, G., Kirwan, B. A., & Anker, S. D. (2018). Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure. Circulation, 137(2), 154-166. https://doi.org/10.1161/CIRCULATIONAHA.117.029968
5. 5.Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, M., Judge, D. P., Barsdorf, A. I., Huber, P., Patterson, T. A., Riley, S., Schumacher, J., Stewart, M., Sultan, M. B., & Rapezzi, C. (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine, 379(11), 1007-1016. https://doi.org/10.1056/NEJMoa1805689
6. 6.Pharmaceutical Benefits Scheme. (2024). Tafamidis and Patisiran - PBS Listings. Australian Government Department of Health. https://www.pbs.gov.au/